In today’s episode, we discuss nervous system repair in the context of traumatic injury and disease with Mike Kelly, the President and CEO of NervGen. With more than three decades of pharmaceutical experience under his belt, Mike plays instrumental roles in the creation, development, and strengthening of a number of pharma companies.
What’s his primary goal? To constantly innovate medical technology for people across the globe…
NervGen is a clinical-stage biotech company advancing innovative therapies for treatments for nervous system damage. Their lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for spinal cord injury. Additionally, they have launched preclinical evaluation for NVG-300 – a new development candidate, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS), and spinal cord injury.
Hit play to find out:
- Where NervGen’s technology comes from.
- What nervous system regeneration looks like at a molecular level.
- How clinical trials progress from animals to humans.
- The ways that biomarker results can indicate breakthroughs in science.
Be sure to follow along with NerGen’s cutting-edge work by visiting their website!
Episode also available on Apple Podcast: http://apple.co/30PvU9C
Boost Your Brainpower with 15% OFF!
Fuel your mind with BrainSupreme Supplements and unlock your full potential. Get 15% OFF your order now using this exclusive link: brainsupreme.co/discount/findinggenius
Hurry—your brain deserves the best!
